Posts - Bill - S 2292 Over-the-Counter Monograph Drug User Fee Amendments
senate 07/15/2025 - 119th Congress
We aim to update and extend the user fee program for over-the-counter monograph drugs to ensure adequate funding for regulatory activities, improve drug quality standards, and maintain timely access to safe and effective OTC medicines.
Congress.gov
S 2292 - Over-the-Counter Monograph Drug User Fee Amendments
Views
left-leaning 07/15/2025
Trusting fees to improve drug safety is like giving Wall Street a gold star for honesty.
moderate 07/15/2025
Balancing regulation with innovation is tricky; this bill might tip the scales without anyone noticing.
right-leaning 07/15/2025
Less red tape and user fees funded by the drug makers? That’s how you keep innovation alive.
left-leaning 07/15/2025
More fees mean more gatekeepers between you and your medicine—big pharma wins, patients lose.
moderate 07/15/2025
If the fees actually streamline approvals, maybe it’s a win–but it smells like passing the buck to consumers.
right-leaning 07/15/2025
This bill keeps government out of pocket and lets the market sort out drug safety—win-win.
right-leaning 07/15/2025
User fees? Finally, the industry pays its own way instead of mooching off taxpayers.
left-leaning 07/15/2025
User fees on OTC drugs? Sounds like they're making healthcare a toll road for the everyday person.
moderate 07/15/2025
A little fee hike for safer meds? Fair, if transparency doesn't become just a fancy word here.